Bausch Health Companies (BHC) Non-Current Assets (2009 - 2026)
Bausch Health Companies' (BHC) quarterly Non-Current Assets came in at $18.5 billion in Q1 2026, down 10.48% year-on-year from $20.7 billion in Q1 2025, and down 8.36% quarter-over-quarter from $20.2 billion in Q4 2025.
Bausch Health Companies (BHC) Non-Current Assets (2009 - 2026) Analysis & Trends
Bausch Health Companies has disclosed Non-Current Assets across 18 years of filings, most recently posting $18.5 billion for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $18.5 billion, down 10.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $80.1 billion (down 4.59% YoY), and the FY2025 annual result was $20.2 billion, down 2.6% from the prior year.
- Non-Current Assets came in at $18.5 billion for Q1 2026 at Bausch Health Companies, down from $20.2 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $23.3 billion in Q1 2022 to a low of $18.5 billion in Q1 2026.
- The 5-year median for Non-Current Assets is $21.2 billion (2023), against an average of $21.2 billion.
- Across the five-year window, Non-Current Assets climbed 1.47% in 2023 and decreased 10.48% in 2026, its largest moves.
- Bausch Health Companies' Non-Current Assets stood at $21.4 billion in 2022, then rose by 1.47% to $21.8 billion in 2023, then declined by 4.62% to $20.7 billion in 2024, then retreated by 2.6% to $20.2 billion in 2025, then retreated by 8.36% to $18.5 billion in 2026.
- The last three Non-Current Assets figures came in at $18.5 billion (Q1 2026), $20.2 billion (Q4 2025), and $20.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 26.33 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 8.68 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 3.84 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 2.47 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 9.64 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.90 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.40 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.22 Bn |
| 10 | Bausch Health Companies | 1.91 Bn | 1.58 Bn | 2.48 Bn | 18.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.52 Bn |
| Dec 31, 2025 | 20.21 Bn |
| Sep 30, 2025 | 20.58 Bn |
| Jun 30, 2025 | 20.75 Bn |
| Mar 31, 2025 | 20.69 Bn |
| Dec 31, 2024 | 20.75 Bn |
| Sep 30, 2024 | 21.19 Bn |
| Jun 30, 2024 | 21.28 Bn |
| Mar 31, 2024 | 21.52 Bn |
| Dec 31, 2023 | 21.75 Bn |
| Sep 30, 2023 | 22.02 Bn |
| Jun 30, 2023 | 21.04 Bn |
| Mar 31, 2023 | 21.21 Bn |
| Dec 31, 2022 | 21.44 Bn |
| Sep 30, 2022 | 22.29 Bn |
| Jun 30, 2022 | 22.75 Bn |
| Mar 31, 2022 | 23.25 Bn |
| Dec 31, 2021 | 23.60 Bn |
| Sep 30, 2021 | 23.93 Bn |
| Jun 30, 2021 | 24.59 Bn |